Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04336254

Recruitment Status : Unknown

Verified March 2021 by Ye Qingsong, Renmin Hospital of Wuhan University.
Recruitment status was: Recruiting

First Posted : April 7, 2020

Last Update Posted : March 10, 2021

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Beijing SH Bio-Tech Corporation, Beijing (CN)

Utooth Biological Technology Co., Ltd. Hubei (CN)

Information provided by (Responsible Party):

Ye Qingsong, Renmin Hospital of Wuhan University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	November 30, 2021
Estimated Study Completion Date :	December 31, 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ye Q, Wang H, Xia X, Zhou C, Liu Z, Xia ZE, Zhang Z, Zhao Y, Yehenala J, Wang S, Zhou G, Hu K, Wu B, Wu CT, Wang S, He Y. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II). Trials. 2020 Jun 12;21(1):520. doi: 10.1186/s13063-020-04380-5.

To Top